Go Deep
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,690 | -0.8 | 6.04 | 1.78 | 168.56 |
| Oct 2026 | 19,649 | -0.8 | 6.11 | 1.78 | 169.96 |
| Oct 2026 | 19,669 | -0.8 | 6.08 | 1.78 | 169.03 |
| Oct 2026 | 20,114 | -0.7 | 5.33 | 1.78 | 147.76 |
| Oct 2026 | 20,134 | -0.7 | 5.29 | 1.78 | 146.97 |
| Oct 2026 | 20,093 | -0.7 | 5.36 | 1.78 | 148.86 |
| Oct 2026 | 19,891 | -0.8 | 5.70 | 1.78 | 157.95 |
| Oct 2026 | 19,346 | -0.9 | 6.62 | 1.78 | 183.12 |
Elicio Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -8,217,000.0 | -11,823,000.0 | -7,718,000.0 | -10,083,000.0 |
| EPS | -0.4 | -0.7 | — | -0.6 |
Elicio Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -39,571,000.0 | -51,898,000.0 | -35,195,000.0 | -28,208,000.0 |
| EPS | -2.6 | -4.2 | -7.0 | -2.7 |
Elicio Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 25,862,000.0 | 28,178,000.0 | 27,146,000.0 | 22,664,000.0 | — |
| Total Liabilities | 24,226,000.0 | 39,490,000.0 | 15,773,000.0 | 124,809,000.0 | — |
| Total Equity | 1,636,000.0 | -11,312,000.0 | 11,373,000.0 | -102,145,000.0 | — |
Owes vs Owns
Elicio Therapeutics, Inc. owed $0.75 for every $1 it owned in Jun 2026, down from $5.51 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.75× | 0.94× | 1.40× | 0.58× | 5.51× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Elicio Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 71.8%Fixed assets (tangible) 19.6%Other assets 8.6%
How it's funded — Dec 2025
Short-term debt 3.9%Long-term debt 36.4%Payables 2.6%Other liabilities 50.8%Shareholders' equity 6.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 18.6 | 17.6 | 12.9 | 6.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 5.1 | 6.2 | 7.3 | 8.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.2 | 4.4 | 7.0 | 8.0 |
| Liabilities & equity | ||||
| Short-term debt | 1.0 | 0.9 | 0.9 | 0.7 |
| Long-term debt | 9.4 | 20.0 | 6.0 | 6.8 |
| Payables | 0.7 | 1.0 | 4.4 | 2.8 |
| Other liabilities | 13.1 | 17.5 | 4.5 | 114.5 |
| Shareholders' equity | 1.6 | -11.3 | 11.4 | -102.1 |
| Net tangible assets | 1.6 | -11.3 | 11.4 | -102.1 |
Elicio Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -36,952,000.0 | -37,068,000.0 | -32,694,000.0 | -22,179,000.0 | — |
| Investing Activities | -16,000.0 | -84,000.0 | -32,000.0 | -654,000.0 | — |
| Financing Activities | 36,695,000.0 | 42,321,000.0 | 38,613,000.0 | 21,202,000.0 | — |